BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31445736)

  • 1. A Patient with EGFR Exon 20 Insertion-Mutant Non-Small Cell Lung Cancer Responded to Osimertinib plus Cetuximab Combination Therapy.
    Fang W; Huang Y; Gan J; Hong S; Zhang L
    J Thorac Oncol; 2019 Sep; 14(9):e201-e202. PubMed ID: 31445736
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
    Hasegawa H; Yasuda H; Hamamoto J; Masuzawa K; Tani T; Nukaga S; Hirano T; Kobayashi K; Manabe T; Terai H; Ikemura S; Kawada I; Naoki K; Soejima K
    Lung Cancer; 2019 Jan; 127():146-152. PubMed ID: 30642543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations.
    Lee Y; Kim TM; Kim DW; Kim S; Kim M; Keam B; Ku JL; Heo DS
    J Thorac Oncol; 2019 Sep; 14(9):1556-1566. PubMed ID: 31108249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion.
    Dagogo-Jack I; Piotrowska Z; Cobb R; Banwait M; Lennerz JK; Hata AN; Digumarthy SR; Sequist LV
    J Thorac Oncol; 2019 Oct; 14(10):e226-e228. PubMed ID: 31558234
    [No Abstract]   [Full Text] [Related]  

  • 5. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
    Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
    White MN; Piotrowska Z; Stirling K; Liu SV; Banwait MK; Cunanan K; Sequist LV; Wakelee HA; Hausrath D; Neal JW
    Clin Lung Cancer; 2021 May; 22(3):201-209. PubMed ID: 33610453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Responder of Gefitinib Plus Crizotinib in Osimertinib Failure EGFR-mutant NSCLC-Resistant With Newly Identified STRN-ALK by Next-Generation Sequencing.
    Zhou C; Zeng L; Zhang Y; Yang N
    J Thorac Oncol; 2019 Jul; 14(7):e143-e144. PubMed ID: 31235037
    [No Abstract]   [Full Text] [Related]  

  • 8. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
    Rangachari D; To C; Shpilsky JE; VanderLaan PA; Kobayashi SS; Mushajiang M; Lau CJ; Paweletz CP; Oxnard GR; Jänne PA; Costa DB
    J Thorac Oncol; 2019 Nov; 14(11):1995-2002. PubMed ID: 31377341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
    Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage Chemotherapy Following Osimertinib in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Tone M; Inomata M; Awano N; Kuse N; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Izumo T
    Anticancer Res; 2020 Apr; 40(4):2239-2246. PubMed ID: 32234920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.
    Planchard D; Boyer MJ; Lee JS; Dechaphunkul A; Cheema PK; Takahashi T; Gray JE; Tiseo M; Ramalingam SS; Todd A; McKeown A; Rukazenkov Y; Ohe Y
    Clin Cancer Res; 2019 Apr; 25(7):2058-2063. PubMed ID: 30659024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in
    Girard N; Moro-Sibilot D; Bouée S; Emery C; Torreton E; Le Lay K; Luciani L; Maritaz C; Chouaid C
    Future Oncol; 2020 Jun; 16(16):1115-1124. PubMed ID: 32352321
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive
    Yu HA; Paz-Ares LG; Yang JC; Lee KH; Garrido P; Park K; Kim JH; Lee DH; Mao H; Wijayawardana SR; Gao L; Hozak RR; Chao BH; Planchard D
    Clin Cancer Res; 2021 Feb; 27(4):992-1002. PubMed ID: 33046516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
    Fang W; Huang Y; Hong S; Zhang Z; Wang M; Gan J; Wang W; Guo H; Wang K; Zhang L
    BMC Cancer; 2019 Jun; 19(1):595. PubMed ID: 31208370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib.
    Fang W; Gan J; Huang Y; Zhou H; Zhang L
    J Thorac Oncol; 2019 Dec; 14(12):e274-e275. PubMed ID: 31757379
    [No Abstract]   [Full Text] [Related]  

  • 16. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
    Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
    Poels KE; Schoenfeld AJ; Makhnin A; Tobi Y; Wang Y; Frisco-Cabanos H; Chakrabarti S; Shi M; Napoli C; McDonald TO; Tan W; Hata A; Weinrich SL; Yu HA; Michor F
    Nat Commun; 2021 Jun; 12(1):3697. PubMed ID: 34140482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
    Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
    Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential afatinib and osimertinib in patients with
    Hochmair MJ; Morabito A; Hao D; Yang CT; Soo RA; Yang JC; Gucalp R; Halmos B; Märten A; Cufer T
    Future Oncol; 2020 Dec; 16(34):2799-2808. PubMed ID: 32854536
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation.
    Yamaguchi O; Kaira K; Kawasaki T; Mouri A; Hashimoto K; Shiono A; Shinomiya S; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Mochida S; Kagamu H
    Thorac Cancer; 2020 Apr; 11(4):1045-1051. PubMed ID: 32068351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.